Domínguez Meijide, AntonioParrales, ValeriaVasili, EftychiaGonzález Lizárraga, FlorenciaKönig, AnnekatrinLázaro, Diana F.Lannuzel, AnnieHaik, StéphaneDel Bel, ElaineChehín, RosanaRaisman Vozari, RitaMichel, Patrick P.Bizat, NicolasOuteiro, Tiago Fleming2021-02-052021-02-052021Neurobiology of Disease, Volume 151, April 2021, 1052560969-9961http://hdl.handle.net/10347/24391Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are neurodegenerative disorders characterized by the misfolding and aggregation of alpha-synuclein (aSyn). Doxycycline, a tetracyclic antibiotic shows neuroprotective effects, initially proposed to be due to its anti-inflammatory properties. More recently, an additional mechanism by which doxycycline may exert its neuroprotective effects has been proposed as it has been shown that it inhibits amyloid aggregation. Here, we studied the effects of doxycycline on aSyn aggregation in vivo, in vitro and in a cell free system using real-time quaking induced conversion (RT-QuiC). Using H4, SH-SY5Y and HEK293 cells, we found that doxycycline decreases the number and size of aSyn aggregates in cells. In addition, doxycycline inhibits the aggregation and seeding of recombinant aSyn, and attenuates the production of mitochondrial-derived reactive oxygen species. Finally, we found that doxycycline induces a cellular redistribution of aggregates in a C.elegans animal model of PD, an effect that is associated with a recovery of dopaminergic function. In summary, we provide strong evidence that doxycycline treatment may be an effective strategy against synucleinopathieseng© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)Attribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Alpha-synucleinParkinson's diseaseDoxycyclineAggregationC. elegansjournal article10.1016/j.nbd.2021.105256open access